Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)
NCT02854761
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Recurrent Respiratory Papillomatosis
Interventions
DRUG:
EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Sponsor
Efranat Ltd.